Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
9.12 USD | +6.67% | -19.36% | -.--% |
Apr. 22 | Guggenheim Starts Coverage on Boundless Bio With Buy Rating, $24 Price Target | MT |
Apr. 22 | Piper Sandler Starts Audentes Therapeutics With Overweight Rating, $20 Price Target | MT |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 203M |
---|---|---|---|---|---|
Net income 2024 * | -68M | Net income 2025 * | -94M | EV / Sales 2024 * | - |
Net cash position 2024 * | 30.75M | Net cash position 2025 * | 36.28M | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-2.72
x | P/E ratio 2025 * |
-2.45
x | Employees | 72 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 88.54% |
1 day | +6.67% | ||
1 week | -19.36% | ||
1 month | -7.88% |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 9.12 | +6.67% | 33,912 |
24-05-30 | 8.55 | -1.95% | 41,075 |
24-05-29 | 8.72 | -9.17% | 58,323 |
24-05-28 | 9.6 | -15.12% | 117,276 |
24-05-24 | 11.31 | +7.51% | 316,234 |
Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-.--% | 203M | |
+11.91% | 118B | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.82% | 21.96B | |
-10.12% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B |
- Stock Market
- Equities
- BOLD Stock